WallStSmart

Pfizer Inc (PFE)vsVuzix Corp Cmn Stk (VUZI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 996286% more annual revenue ($62.58B vs $6.28M). PFE leads profitability with a 12.4% profit margin vs 0.0%. PFE earns a higher WallStSmart Score of 49/100 (D+).

PFE

Hold

49

out of 100

Grade: D+

Growth: 2.0Profit: 6.5Value: 3.3Quality: 4.8
Piotroski: 3/9

VUZI

Avoid

26

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: -4.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

PFESignificantly Overvalued (-192.3%)

Margin of Safety

-192.3%

Fair Value

$9.25

Current Price

$27.04

$17.79 premium

UndervaluedFair: $9.25Overvalued

Intrinsic value data unavailable for VUZI.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PFE4 strengths · Avg: 8.3/10
Market CapQuality
$153.81B9/10

Large-cap with strong market position

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.9%8/10

Strong operational efficiency at 23.9%

Free Cash FlowQuality
$4.50B8/10

Generating 4.5B in free cash flow

VUZI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
76.3%10/10

Revenue surging 76.3% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

PFE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.2%2/10

Revenue declined 1.2%

EPS GrowthGrowth
-21.3%2/10

Earnings declined 21.3%

VUZI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$180.45M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-89.7%2/10

ROE of -89.7% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : PFE

The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.

Bull Case : VUZI

The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.

Bear Case : VUZI

The primary concerns for VUZI are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

PFE profiles as a declining stock while VUZI is a hypergrowth play — different risk/reward profiles.

VUZI carries more volatility with a beta of 1.31 — expect wider price swings.

VUZI is growing revenue faster at 76.3% — sustainability is the question.

PFE generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

PFE scores higher overall (49/100 vs 26/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Vuzix Corp Cmn Stk

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.

Want to dig deeper into these stocks?